Stiris Research Inc. Announces Successful Completion of Clinical Study Report for a Phase IB Study in Uveal Melanoma

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the successful completion of the Clinical Study Report (CSR) for an Australian biotech’s Phase Ib Open label study in Uveal Melanoma study.

“We are extremely grateful for the opportunity to have worked on this critically important treatment study for patients with Uveal Melanoma. It is always rewarding seeing a long running program come to an end and concluding that work by compiling data with the biostatisticians and medical writers. We are always excited when a project comes to an end that has allowed us to be involved in a study for those with limited treatment choices.” Amanda Carrera, Vice President.

Uveal melanoma, the most common primary intraocular tumor, has an associated approximate 40% risk of metastasizing to the liver within 10 years of diagnosis of the primary tumor. Hepatic metastases, which occur in 95% of patients with metastatic uveal melanoma, result in death in almost all cases.

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472306/#:~:text=Uveal%20melanoma%2C%20the%20most%20common,diagnosis%20of%20the%20primary%20tumor.&text=Hepatic%20metastases%2C%20which%20occur%20in,death%20in%20almost%20all%20cases)